Niveau, A Phase 3 Study For Pts With B- Or T-Cell Aggressive Non-Hodgkin Lymphoma In First Relapse Or Progression Not Eligible For High-Dose Chemotherapy (Hdt), Testing Nivolumab In Combination With Gemcitabine, Oxaliplatin (Gemox), Plus Rituximab (R) In Case Of B-Cell Lymphoma

Background: Relapse of aggressive B-cell as well as peripheral T-cell lymphoma (PTLC) has a very poor prognosis, especially in pts ineligible for high-dose chemotherapy. Nivolumab, a human anti-PD1 antibody has the potential to increase rituximab-mediated effector mechanisms and to target the microenvironment in Non-Hodgkin lymphoma. Addition of nivolumab might also increase the efficacy of conventional chemotherapy. Therefore, the NIVEAU trial is testing a common conventional chemotherapy regimen (R)-GemOx vs. Nivolumab plus (R)-GemOx